Enhancing Team Collaboration for Better Results

Jun 16, 2025

660 likes | 764 Vues

Explore strategies and tools to improve teamwork and achieve successful outcomes. Learn how to foster communication, trust, and synergy among team members. Discover best practices for effective collaboration in various projects and environments.

Share Presentation

Embed Code

leland

Télécharger la présentation

Enhancing Team Collaboration for Better Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Figure 19-1a
Figure 19-1b
Figure 19-1c
Figure 19-1d–e
Figure 19-1d
Figure 19-1e
Figure 19-1f
Figure 19-1g
Figure 19-1h
Figure 19-1i
Figure 19-1j
Figure 19-2
Table 19-1
Figure 19-3
Figure 19-4 - Overview
Figure 19-4a
Figure 19-4b
Figure 19-4c
Figure 19-4d
Figure 19-5
Figure 19-6
Figure 19-7
Figure 19-8 - Overview
Figure 19-8a
Figure 19-8b
Figure 19-8c
Figure 19-8d
Figure 19-9 - Overview
Figure 19-9a
Figure 19-9b
Figure 19-10 - Overview
Figure 19-10, step 1
Figure 19-10, step 2
Figure 19-10, step 3
Figure 19-10, step 4
Figure 19-10, step 5
Figure 19-11 - Overview
Figure 19-11, step 1
Figure 19-11, step 2
Figure 19-11, step 3
Figure 19-11, step 4
Figure 19-12 - Overview
Figure 19-12, step 1
Figure 19-12, step 2
Figure 19-13 - Overview
Figure 19-13, step 1
Figure 19-13, step 2
Figure 19-13, step 3
Figure 19-14
Figure 19-15 - Overview

Figure M.1a: MEA Bulk Supply Demand

Figure M.1a: MEA Bulk Supply Demand. Figure M.1b: PEA Bulk Supply Demand. Figure M.2- EGAT Direct Customers Demand, Peak Day. Figure M.3a: MEA Customer Demand by Tariff Classification, Working Day. Figure M.3b: MEA Customer Demand by Tariff Classification, Working Day.

341 views • 17 slides

Supplementary figure 1A

Supplementary Figure 1: Comparison of the results obtained from three widely used databases (namely AmiGO, ArrayExpress and GeneCards ) with that from HypoxiaDB . A specific protein PGK1 is searched in HypoxiaDB and in the other databases. The results were compared.

197 views • 8 slides

Supplementary Figure 1A: non-inflamed tonsil

Supplementary Figure 1A: non-inflamed tonsil. #1. #7. #2. #8. #3. #9. #10. #4. #5. #11. #6. #12. Supplementary Figure 1B: chronic tonsillitis. #1. #7. #2. #8. #3. #9. #10. #4. #5. #11. #6. #12.

111 views • 2 slides

August 19, 2013 English 1A

August 19, 2013 English 1A. Vocabulary.

89 views • 2 slides

August 19, 2013 English 1A

August 19, 2013 English 1A.

104 views • 3 slides

Supplementary Figure 1A

Supplementary Figure 1A. Patients with HCC. Patients with No HCC. Model building n = 255. 14.5 %. Yes. No. HBV. n = 35. n = 220. 10.0 %. 42. %. Male. Female. Group 1. Sex. n = 100. n = 120. 3.0 %. 15.8%. Yes. No. Group 2. Exogenous insulin. n = 13. n = 107.

172 views • 4 slides

Figure 1a:

Figures from : Thompson, D.W.J., and J.M. Wallace, 2000: Annular modes in the extratropical circulation. Part I: Month-to-month variability. J. Climate , 13, 1000-1016. Figure 1a:.

309 views • 8 slides

Gentile et al., Figure 1A

A. B. Gentile et al., Figure 1A. C. Gentile et al., Supplementary Figure 1

136 views • 1 slides

Figure 1A.

Figure 2. Figure 1A. anti-Epo ab. Streptavidin-HRPO. Adult bone marrow. Epo-biotin (µg). 36. 18. 9. 4.5. 36. 18. 9. 4.5. CD117-. CD117+.

122 views • 1 slides

Supplemental D ata Figure 1A

120 views • 3 slides

Figure 1A

A. ADV. ADV+LAM. 8. 500. 400. 6. 300. HBV DNA (Log IU/mL). ALT (IU/mL). 4. 200. 2. 100. 0. 0. M0. M7. M14. M21. M28. M35. M42. M48. M56. Months of therapy. Figure 1A. Figure 1B. B. ADV. ADV+LAM. 10. 1000. 8. 800. 600. 6. HBV DNA (Log IU/mL). ALT (IU/mL). 4.

157 views • 7 slides

Figure 1a

Incidence of experimental BA. *. Incidence in [%]. *p<0.05. Figure 1a. Balb/c Black/6 died died. Survival [%]. days after RRV infection . Figure 1b. CD3 lymphocytes. *. *. *. 30. 20. T cells/0.25 mm 2. 10. 0. +BA - BA cont +BA - BA cont.

163 views • 5 slides

Figure 1a-e, supplement

e. a. b. unstimulated. +fMLP. T308P-Akt. S473P-Akt. Akt. c. d. (min). 0 0.5 1 1.5 2 4. + fMLP (100 nM). PH-Akt-GFP. Anti-PIP 3 antibody. Figure 1a-e, supplement. f. (min). 0. 1. 1.5. 0.5. 2. 4. + fMLP (100 nM). Figure 1f, supplement. a. Overlay. DiD.

204 views • 8 slides

SUPPLEMENTARY TABLE 1b TISSUE CODES FOR FIGURE 1a

SUPPLEMENTARY TABLE 1b TISSUE CODES FOR FIGURE 1a.

102 views • 1 slides

Figure 1a

Figure 1a.

80 views • 1 slides

Supplementary Figure 1A

Supplementary Figure 1A. Supplementary Figure 1B. PCLB1. HNF4A. WNT5A. VANGL1.

265 views • 11 slides

Supplementary Figure 1A (male)

Etiocholanolone -S. DHEA-S. P<0.01. P<0.01. 16-OH-DHEA-S. 16/D. P<0.01. P<0.01. 16/E. F0-2 F3-4. P<0.01. Supplementary Figure 1A (male). F0-2 F3-4. DHEA-S. Etiocholanolone -S. N.S. P<0.05. 16-OH-DHEA-S. 16/D. N.S. P<0.01. 16/E. P<0.01.

159 views • 2 slides